These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17565473)

  • 1. [Malignant hyperthermia. The ugly].
    Rüffert H; Wehner M; Deutrich C; Olthoff D
    Anaesthesist; 2007 Sep; 56(9):923-9. PubMed ID: 17565473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Malignant hyperthermia].
    Urwyler A; Hartung E
    Anaesthesist; 1994 Aug; 43(8):557-69. PubMed ID: 7978181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant hyperthermia and excitation-contraction coupling.
    Melzer W; Dietze B
    Acta Physiol Scand; 2001 Mar; 171(3):367-78. PubMed ID: 11412150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant hyperthermia: update on susceptibility testing.
    Litman RS; Rosenberg H
    JAMA; 2005 Jun; 293(23):2918-24. PubMed ID: 15956637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells.
    Sato K; Roesl C; Pollock N; Stowell KM
    Anesthesiology; 2013 Jul; 119(1):111-8. PubMed ID: 23459219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
    Monnier N; Lunardi J
    Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rare genetic variant of the ryanodine receptor in a suspected malignant hyperthermia susceptible patient.
    MacKay EJ; Wilkerson C; Kraeva N; Rosenberg H; Kennedy T
    J Clin Anesth; 2016 Sep; 33():144-6. PubMed ID: 27555149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Malignant hyperthermia].
    Metterlein T; Schuster F; Graf BM; Anetseder M
    Anaesthesist; 2014 Dec; 63(12):908-18. PubMed ID: 25384957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Malignant hyperthermia--diagnostics, treatment and anaesthetic management].
    Schuster F; Müller-Reible CR
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2009 Nov; 44(11-12):758-63; quiz 764. PubMed ID: 19918708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].
    Wappler F; Scholz J; von Richthofen V; Fiege M; Steinfath M; Schulte am Esch J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Sep; 32(9):541-8. PubMed ID: 9417254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current aspects of the diagnosis of malignant hyperthermia].
    Rüffert H; Olthoff D; Deutrich C; Froster UG
    Anaesthesist; 2002 Nov; 51(11):904-13. PubMed ID: 12434264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant hyperthermia: clinical and molecular aspects.
    Correia AC; Silva PC; da Silva BA
    Rev Bras Anestesiol; 2012; 62(6):820-37. PubMed ID: 23176990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant hyperthermia.
    Hopkins PM; Gupta PK; Bilmen JG
    Handb Clin Neurol; 2018; 157():645-661. PubMed ID: 30459030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).
    Ta TA; Pessah IN
    Neurotoxicology; 2007 Jul; 28(4):770-9. PubMed ID: 17023049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant hyperthermia: a pharmacogenetic disorder.
    Stratman RC; Flynn JD; Hatton KW
    Orthopedics; 2009 Nov; 32(11):835. PubMed ID: 19902883
    [No Abstract]   [Full Text] [Related]  

  • 17. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
    Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
    Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Neuromuscul Disord; 2004 Jul; 14(7):429-37. PubMed ID: 15210166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA.
    Sato K; Pollock N; Stowell KM
    Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.